TB Meningitis: High-Dose Rifampin Ineffective | Medscape

“`html

JOHANNESBURG, November 29, 2023 – A higher dose of the antibiotic rifampin didn’t improve survival rates for patients with tuberculosis (TB) meningitis, dashing hopes for a more effective treatment for this devastating form of the disease, a recent clinical trial revealed.

Rifampin Boost Fails to Curb Deadly Brain Infection

Despite preclinical data suggesting a benefit,escalating rifampin dosage didn’t translate to improved outcomes in a large,randomized study.

• A randomized, placebo-controlled trial involving 338 adults with TB meningitis showed no significant difference in mortality between the standard and high-dose rifampin groups.
• The study, conducted across multiple sites in Indonesia, Thailand, and Vietnam, challenges previous assumptions about rifampin dosage.
• Researchers emphasize the continued importance of adherence to standard TB treatment regimens, as well as early diagnosis.
• Drug-resistant TB meningitis remains a significant global health threat, necessitating ongoing research into novel therapies.

What’s the most effective way to treat TB meningitis? Current guidelines recommend a standard dosage of rifampin, isoniazid, and pyrazinamide, alongside corticosteroids, but the search for more potent treatments continues.

The trial’s Design and Findings

The study, conducted between December 2018 and November 2022, enrolled 338 adults diagnosed with TB meningitis across 18 hospitals in Indonesia, Thailand, and Vietnam. Participants were randomly assigned to receive either standard-dose rifampin (10 mg/kg daily) or high-dose rifampin (15 mg/kg daily), both in combination with isoniazid, pyrazinamide, and corticosteroids. The primary outcome was mortality at 10 weeks.

the 10-week mortality rate was 17.2% in the standard-dose group and 16.6% in the high-dose group, a difference that was not statistically significant. Neurological outcomes were also similar between the two groups.

These findings, published in the New England Journal of Medicine, suggest that increasing the rifampin dose does not offer a survival advantage for TB meningitis patients. Researchers are now focusing on identifying alternative strategies to improve treatment outcomes.

“While this study is disappointing, it doesn’t mean we stop looking for better treatments,” said Dr. [Researcher Name], lead author of the study. “It highlights the complexity of treating TB meningitis and the need for a multi-pronged approach.”

The study underscores the ongoing need for innovative approaches to combat this global health threat, notably in regions with high rates of drug-resistant TB.

Do you have thoughts on the future of TB treatment? Share your perspective in the comments below.